Routine board and committee reshuffling with no operational or strategic catalysts. No trading implications — monitor upcoming pipeline updates or financial filings for material events.
Price Chart
Executive Summary
Chemomab Therapeutics appointed Gwen Melincoff as a new independent director and chair of the nominating and governance committee, replacing Claude Nicaise and Jill Quigley who resigned without disagreement. The board also shuffled audit committee members. These are routine governance changes with no material financial or strategic impact.
Key Facts
- Gwen Melincoff appointed as Class I Director and chair of nominating and governance committee, effective June 1, 2026
- Claude Nicaise resigned as director and audit committee member on May 29, 2026
- Jill Quigley resigned as director and audit committee member on May 29, 2026
- Neither resignation was due to any disagreement with the company
- Neil Cohen and Nissim Darvish appointed to audit committee on June 1, 2026
- Neil Cohen resigned as nominating committee chair, replaced by Gwen Melincoff
- Board size set at five directors
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- No identified risks from this filing — routine governance changes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-003058 |
| Document: 0001178913-26-003058-index-headers.html | 0001178913-26-003058 |
| Document: 0001178913-26-003058-index.html | 0001178913-26-003058 |
| Document: 0001178913-26-003058.txt | 0001178913-26-003058 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | 6-K | $2.09 $2.80 | ▲ +33.97% | ▲ +35.92% | $1.30 (−37.80%) |
Aug 19, 2026 6w ago | Press Release | $2.09 $2.80 | ▼ −33.97% | ▼ −35.92% | $1.30 (+37.80%) |
Jul 8, 2026 12w ago | 6-K | $1.97 $1.75 | ▼ −11.17% | ▼ −14.44% | $1.30 (−34.01%) |
Jun 2, 2026 17w ago | 6-K | $1.72 $2.27 | ▲ +31.98% | ▲ +32.98% | $1.30 (−24.42%) |
May 14, 2026 20w ago | 6-K | $1.70 $1.65 | ▼ −2.94% | ▼ −2.08% | $1.30 (−23.53%) |
May 14, 2026 20w ago | Press Release | $1.70 $1.65 | ▼ −2.94% | ▼ −2.08% | $1.30 (−23.53%) |
May 6, 2026 21w ago | 6-K | $1.74 $1.72 | ▼ −1.15% | ▼ −4.29% | $1.30 (−25.29%) |
Mar 19, 2026 28w ago | Press Release | $1.93 $1.67 | ▼ −13.47% | ▼ −21.09% | $1.30 (−32.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access